Physician profile
Steven Mark Bloom
NPI 1346224409
$5,992.62
in general payments reported to CMS, 2019-2025
25 companies · $380 in 2025
The $380 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $179 · 2021: $276 · 2022: $707 · 2023: $534 · 2024: $3,522 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,365 · Food and Beverage: $1,321 · Travel and Lodging: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,365.00 |
| Food and Beverage | $1,320.82 |
| Travel and Lodging | $750.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,115.10 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $762.96 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $452.30 | 2019-2022 | |
| Genentech USA, INC. | $439.65 | 2019-2025 | Vabysmo |
| Abbvie INC. | $150.12 | 2022-2025 | Xen Glaucoma Treatment System |
| Alcon Vision LLC | $149.31 | 2022-2023 | Argos, Hydrus Microstent, Clareon |
| Ani Pharmaceuticals, INC. | $125.19 | 2024-2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Allergan, INC. | $89.78 | 2019-2021 | |
| Alimera Sciences, INC. | $73.31 | 2019-2024 | Iluvien, Yutiq |
| Mallinckrodt Hospital Products INC. | $70.76 | 2023-2025 | Acthar |
| Biogen, INC. | $68.91 | 2022-2023 | |
| Horizon Therapeutics Plc | $65.50 | 2021-2022 | |
| Ocular Therapeutix, INC. | $64.65 | 2022-2023 | Dextenza |
| Oyster Point Pharma, INC. | $50.68 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $44.24 | 2023-2024 | Xipere, Visudyne |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $43.49 | 2022 | |
| Apellis Pharmaceuticals, INC. | $34.50 | 2022-2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $34.24 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.08 | 2019-2021 | |
| Biotissue Holdings INC. | $30.69 | 2019-2022 | |
| Dompe US, INC. | $29.11 | 2025 | Oxervate |
| Astellas Pharma US INC | $24.33 | 2023 | |
| Amgen INC. | $15.19 | 2024 | Tepezza |
| Sun Pharmaceutical Industries INC. | $14.16 | 2024 | |
| Spark Therapeutics, INC. | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.